GlassScriptPhysician profile
Amanda K Malone
NPI 1871512269
$1,092.15
in general payments reported to CMS, 2019-2025
19 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.61 · 2021: $140 · 2022: $237 · 2023: $260 · 2024: $134 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $697.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $371.94 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $96.33 | 2021-2023 | |
| Lilly USA, LLC | $89.21 | 2022-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $79.61 | 2022-2025 | Capvaxive, Gardasil 9 |
| Exact Sciences Corporation | $59.94 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Idorsia Pharmaceuticals US INC | $51.88 | 2023 | Quviviq |
| Pfizer INC. | $45.98 | 2021-2022 | |
| Glaxosmithkline, LLC. | $44.38 | 2022-2023 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $40.64 | 2023-2025 | Airsupra, Farxiga |
| Amgen INC. | $29.27 | 2024 | Prolia, Evenity |
| Astellas Pharma US INC | $25.24 | 2025 | Veozah |
| Mylan Specialty L.P. | $22.91 | 2023 | Yupelri |
| Abbott Laboratories | $21.42 | 2022 | |
| Optinose US, INC. | $20.82 | 2021 | |
| Phathom Pharmaceuticals, INC. | $20.33 | 2024 | Voquezna |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $18.89 | 2024 | Senza |
| Novartis Pharmaceuticals Corporation | $18.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.75 | 2023 | |
| Resmed Corp | $17.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Malone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.